KarX-EC matching placebo
Sponsors
Bristol-Myers Squibb Services Unlimited Company
Conditions
Agitation Associated with
Alzheimer’s DiseaseAgitation Associated with Alzheimer’s DiseaseMild to moderate Alzheimer’s Disease
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-1)
RecruitingCTIS2025-520613-31-00
Start: 2025-10-31Target: 101Updated: 2025-11-14
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)
RecruitingCTIS2025-520746-30-00
Start: 2025-11-18Target: 225Updated: 2025-11-05
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
RecruitingCTIS2025-520747-32-00
Start: 2025-10-29Target: 292Updated: 2026-01-26
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate
the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with
Alzheimer’s Disease (ADAGIO-2)
RecruitingCTIS2025-520612-34-00
Start: 2025-11-28Target: 90Updated: 2025-10-26